Pharvaris at the Global Healthcare Conference
ZUG, Switzerland – Pharvaris, a pioneering biopharmaceutical innovator, focuses on developing oral bradykinin B2 receptor antagonists aimed at catering to the needs of those suffering from bradykinin-mediated diseases. Specifically, these diseases include hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). The company has recently announced its participation in a prominent event, the Leerink Partners Global Healthcare Conference, which will be held from March 10 to March 12, 2025.
Event Details and Keynote
Scheduled to take place at the W South Beach Hotel in Miami, this conference represents a significant opportunity for Pharvaris to connect with stakeholders and highlight its advancements in therapies aimed at improving patient outcomes. The format of Pharvaris's presentation will be a fireside chat featuring Berndt Modig, the company’s CEO, who will provide insights into their innovative approaches and future directions.
Timing and Access
The presentation is set for Monday, March 10, at 9:20 a.m. ET. For those unable to attend in person, Pharvaris will offer a live audio webcast accessible through the investor relations section of their official website. This initiative allows a broader audience to get a glimpse of the discussion surrounding cutting-edge treatments and the company’s future strategies. The replay of this presentation will be available for 30 days, ensuring that those interested can stay informed.
Innovative Treatments by Pharvaris
Pharvaris aims to redefine the landscape of treatment for bradykinin-mediated angioedema through its groundbreaking oral bradykinin B2 receptor antagonists. The company is on a mission to provide therapies that deliver an injectable-like efficacy with the added comfort and convenience of oral administration. This is particularly significant for patients dealing with chronic conditions like HAE, as it provides a new level of flexibility and ease when managing their health.
Clinical Development Progress
Pharvaris boasts promising results from its clinical trials, notably in Phase 2 studies assessing the prophylactic use of their candidate drugs and their on-demand treatment capabilities for HAE. Currently, they are pushing ahead with pivotal Phase 3 studies: one focused on the prevention of HAE attacks (CHAPTER-3) and another targeting the on-demand treatment of HAE attacks (RAPIDe-3). This vital phase of testing is crucial for validating the efficacy and safety of their developments, marking a significant milestone in improving quality of life for patients.
Commitment to Patients and Future Outlook
Pharvaris remains committed to advancing healthcare solutions that cater to the unmet needs of patients suffering from rare diseases. Their focus on innovative treatments not only highlights the potential for enhanced patient care but underscores the importance of medical research in transforming lives. As they participate in conferences such as the Leerink Partners Global Healthcare Conference, Pharvaris looks forward to sharing their journey and continuing to engage with the healthcare community.
Frequently Asked Questions
1. What is the purpose of the Leerink Partners Global Healthcare Conference?
The conference serves as a platform for companies like Pharvaris to showcase their innovations and connect with investors and industry experts.
2. Who will represent Pharvaris at the event?
CEO Berndt Modig will represent Pharvaris during the fireside chat at the conference.
3. When is Pharvaris scheduled to present?
Pharvaris is set to present on Monday, March 10, at 9:20 a.m. ET.
4. How can I access the live presentation?
The live audio webcast can be accessed through the investor relations section of the Pharvaris website.
5. What are the key areas of research for Pharvaris?
Pharvaris is focused on developing oral treatments for bradykinin-mediated angioedema, aiming to improve efficacy and patient tolerability.
